DocStoX is a free AI-powered research platform for Indian equity markets, covering 6,800+ NSE & BSE stocks with prices, fundamentals, 326 financial ratios, shareholding, FII/DII flows, F&O, IPOs, a visual screener and AI stock scoring.

Yes. DocStoX has a free tier covering stock research, the screener, FII/DII data and educational guides, plus a free MCP API tier (50 tool calls/day) for AI assistants. A Pro plan adds higher limits and advanced features.

What data does DocStoX cover?

Every NSE & BSE listed stock (6,800+ instruments): EOD and intraday prices, income statement / balance sheet / cash flow, 326 ratios, quarterly shareholding, promoter pledge, mutual-fund holdings, FII/DII flows, F&O and option-chain data, analyst forecasts, IPOs, corporate actions and news.

Can AI assistants like ChatGPT or Claude use DocStoX data?

Yes. DocStoX runs a public Model Context Protocol (MCP) server at https://mcp.docstox.com/mcp with 39 tools, so Claude, ChatGPT, Cursor and other MCP clients can pull Indian market data directly. Setup and a free key are at https://docstox.com/mcp.

What is the VALIANT LABORATORIES LTD (VALIANTLAB) share price today?

VALIANT LABORATORIES LTD (VALIANTLAB) is trading at ₹63.44 on the NSE, down 0.25% on the day. Source: DocStoX.

What is the market capitalisation of VALIANT LABORATORIES LTD?

VALIANT LABORATORIES LTD has a market capitalisation of approximately ₹373 crore.

VALIANT LABORATORIES LTD

VALIANTLAB·NSE·Healthcare

₹63.44▼ -0.16 (-0.25%)

Healthcare · Pharmaceuticals

Revenue under pressure recently

Day₹61.20

₹64.45

52W₹50

₹10724%

Open

₹63.60

High

₹64.45

Low

₹61.20

Prev Close

₹63.60

Volume

7.5K

VWAP

₹62.53

Snapshot

Key fundamentals

Market Cap

₹373 Cr

P/E Ratio

N/A

P/B Ratio

1.13

EPS

₹-0.60

Book Value

₹57.20

ROE

-1.20%Weak

ROCE

1.00%Weak

Dividend Yield

0.00%

Debt / Equity

0.15Low

Face Value

₹10.00

52W High

₹106.85

52W Low

₹49.51

Sector

Healthcare

Industry

Pharmaceuticals

Avoid

Narrow moatHigh uncertainty

Fair value estimate

₹32

▼ 49.6%downside

Trading at ₹63 — 50% above our estimate

BearFair valueBull

₹27₹32₹37

/100

Business quality — Watch the fundamentals

Growth 0Profitability 0Efficiency 0Valuation 93

Plain English

Our view

Revenue under pressure recently
Low debt relative to equity
Weak returns on equity (-1%)

Strengths

Low debt relative to equity
Promoters hold a controlling stake

Risks

Weak returns on equity (-1%)
Revenue has been shrinking
Fundamental red flags (Piotroski 1/9)

How we got there

Fair value methods

Residual income

-1% ROE fading to 12% over ~10 yrs, on ₹57 book

₹32

Relative P/E

Needs positive EPS

—

Graham floor

Needs positive EPS

—

Analyst target

No analyst coverage

—

Blended fair value₹32

What the numbers say

Investment thesis

Bull case

Low debt relative to equity
Promoters hold a controlling stake

Bear case

Weak returns on equity (-1%)
Revenue has been shrinking
Fundamental red flags (Piotroski 1/9)

Free — see our deterministic Fair Value range, business quality score, and the full bull/bear case for this stock.

Snapshot

Key statistics

P/E

—

ROE

-1.2%Weak

Above 15% is considered healthy for Indian equities

ROCE

1.0%Weak

Above 18% means capital is working hard

Debt/Eq

0.15Low

Below 0.5 is comfortable; above 1.5 strains the balance sheet

Mkt Cap

₹373 Cr

P/B

1.13

EPS

₹-0.60

Div Yield

—

What changed

Recent changes

Foreign investors+0.2% stake last quarter

What matters

News impact

Overview

Valuation

N/A

No P/E

Growth

Shrinking

-11% rev CAGR

Profitability

Loss-making

-1.2% ROE

Financial health

Rock solid

D/E 0.15

Momentum

N/A

No technicals

Today

Trading activity

Delivery %—

Turnover₹4.69L Cr

Trades63

VWAP₹62.53

Face value₹10.00

Market depth

Market depth available during market hours

Snapshot

Technical signals

Compounded annual growth

Growth (CAGR)

Revenue

-10.8%

+5.4%

10Y

—

Profit

—

10Y

—

EPS

—

10Y

—

Profile

Pros

Company has reduced debt.
Stock is trading at 1.08 times its book value
Company is expected to give good quarter

Watch-outs

Cons

Company has low interest coverage ratio.
Company has a low return on equity of -1.41% over last 3 years.
Earnings include an other income of Rs.2.32 Cr.

Forecast

News

Peers

Financials

Growth

Shareholding

Ownership

Ownership breakdown

Quarter ending 31 Mar 2026

Foreign investors bought 0.19 pts last quarter. The QoQ column shows each group's change versus the prior quarter.

75%

Promoter

Promoters

74.9%0.00

Public

18.5%+0.02

FII / FPI

0.2%+0.19

DII

0.0%0.00

Others

6.3%

Total shareholders

14,657-253 QoQ

Quarterly trend

Ownership over time

Q4 FY26

Promoter74.94%

FII0.20%

Public18.53%

Others6.33%

Corporate Actions

Bulk & Block Deals

Filings

MF Holdings

Technicals

FAQs

Quick reference

Frequently asked questions

Incorporated in 1980, Valiant Laboratories Ltd manufactures and deals in Pharmaceuticals and speciality chemicals[1]